Navigation Links
Knee Pain? An Exclusive Study Engineers Cartilage to Match Patient's Own Tissue
Date:1/8/2008

MINNEAPOLIS, Jan. 8 /PRNewswire/ -- Patients with knee cartilage injuries now have the opportunity to re-grow their cartilage as part of an innovative study at TRIA Orthopaedic Center, in Bloomington, MN. Cartilage is the tough but flexible tissue that covers the ends of your bones at a joint such as the knee; symptoms of knee cartilage defects include pain, swelling and catching. In the United States alone, knee pain ranks the second highest source of musculoskeletal-related physician visits in 2005, according to the National Ambulatory Medical Care Survey. This new implant technology, NeoCart(R), regenerates this injury-prone tissue within a bio-engineered material, grown from the patient's own cartilage cells. The matrix matches his or her unique cartilage characteristics, and is being studied as an alternative to a standard therapy called microfracture. Dr. Brad Nelson, Orthopaedic Surgeon and Principal Investigator for TRIA, will be implanting this engineered tissue matrix for a select number of patients.

Histogenics Corporation, makers of NeoCart(R), successfully completed Phase I of the NeoCart(R) clinical trial, demonstrating the safety of the technique in a small number of patients, and is now in Phase II, where NeoCart(R) will be compared with a standard therapy called microfracture. TRIA Orthopaedic Center is one of a limited number of sites in the country, and the only site in Minnesota, chosen to participate in the study. "We are thrilled to be one of five centers nationally participating in this clinical trial," said Ryan Graver, Director of Research and education for TRIA. "This kind of cutting-edge research improves Orthopaedic treatments and outcomes that our patients can expect. Our commitment is to improve care for all Orthopaedic patients and it is through such projects TRIA is beginning to translate science into advancements in clinical care."

Since the body does not naturally re-grow cartilage without medical intervention t
'/>"/>

SOURCE TRIA Orthopaedic Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  ResMed (NYSE: RMD ... definitive agreement to acquire Curative Medical, a ... sleep-disordered breathing medical devices and accessories. ... with ResMed,s global leadership in sleep and respiratory medicine, ... China suffering from sleep-disordered breathing ...
(Date:7/30/2015)... Calif. , July 30, 2015  EP ... /Alcon executives have recently contacted the Company about ... begin as early as Monday, August 3, 2015.  ... quoted as saying that the coming electronic contact ... of dollars over the next several years.  Novartis ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... LIONVILLE, Pa., Dec. 16, 2010 West Pharmaceutical Services, Inc. (NYSE: ... has approved payment of the first-quarter 2011 cash dividend of $0.17 ... to shareholders of record on January 19, 2011. ... of components and systems for injectable drug delivery, including stoppers and ...
... (Nasdaq: HSKA, "Heska" or the "Company"), announced today that ... Forever, has been awarded $25,000 as the grand prize ... (Logo: http://photos.prnewswire.com/prnh/20000622/HESKALOGO) Helping low-income ... their pets for as long as possible, Pets Forever ...
Cached Medicine Technology:Heska Corporation Awards $25,000 Grand Prize to Pets Forever 2
(Date:7/31/2015)... ... 31, 2015 , ... In the most recent testosterone lawsuit news ... District of Illinois, Androgel testosterone attorneys report that a “Mini Status Conference” was held ... recording the minutes of the status conference, which was held that day, according to ...
(Date:7/31/2015)... ... July 31, 2015 , ... People love to feel ... insurance, where price is an important factor to clients when choosing to purchase ... offers the Preferred Producer Multi-Life Discount program, where advisers pass savings onto their ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce ... or More, **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 ... veteran of helping drug, biologic and device firms reduce manufacturing errors by 50 ...
(Date:7/30/2015)... ... 2015 , ... As more hospitals across the country see the value in ... challenge. Because of growing competition, it is more important than ever to market ... The team at Wound Care Advantage has found that while many hospitals ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating ... Lines ." It's for women interested in improving their love lives using specific ... which officially launched to the public early this morning, has drawn praise from ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... introduced the world to personal computers, then the iPod, the iPhone ... cancer. He was 56. "Apple has lost ... amazing human being," the company said in a statement it posted ...
... of strategies released today by the Commonwealth Fund Commission ... how the U.S. health care system serves vulnerable populationsthose ... of racial and ethnic minority groups. According to ... Achieve High Performance Health Care for Vulnerable Populations, closing ...
... AMHERST, Mass. -- New research based on post-hospital arrival ... adjusting for differences in injury severity, gun use, and ... assault, African-Americans have a significantly higher overall post-scene of ... by Anthony R. Harris, emeritus professor of sociology at ...
... 12 or older are estimated to have driven under the ... a 2009 National Survey on Drug Use and Health. While ... its role in causing crashes has remained in question. To ... of a car accident, researchers at Columbia University did a ...
... and run and how their knees look in an MRI ... decades in advance whether they will develop osteoarthritis, the common ... the time they reach the age of 70. Doctors ... scan and tell you definitively whether or not they will ...
... (HealthDay News) -- Technology that directly oxygenates the blood reduced ... by the H1N1 flu virus, a new British study shows. ... they noted that debate continues about the use of the ... called extracorporeal membrane oxygenation, which oxygenates the blood. It,s used ...
Cached Medicine News:Health News:Steve Jobs, Visionary Leader of Apple Inc., Dies at 56 2Health News:Steve Jobs, Visionary Leader of Apple Inc., Dies at 56 3Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 2Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 3Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 4Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 5Health News:Researchers find race disparity in post-hospital arrival homicide deaths at trauma centers 2Health News:Marijuana use may double the risk of accidents for drivers 2Health News:$6.3 million center at UCSF and UC Davis seeks ways to diagnose and prevent osteoarthritis 2Health News:$6.3 million center at UCSF and UC Davis seeks ways to diagnose and prevent osteoarthritis 3Health News:Oxygenating Blood of Hospitalized H1N1 Flu Patients Saved Lives: Study 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: